Cargando…
Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations
Trazodone is approved for the treatment of major depressive disorders, marketed as immediate release (IR), prolonged release, and once a day (OAD) formulation. The different formulations allow different administration schedules and may be useful to facilitate patients’ compliance to the antidepressa...
Autores principales: | Oggianu, Laura, Di Dato, Giorgio, Mangano, Giorgina, Rosignoli, Maria Teresa, McFeely, Savannah, Ke, Alice Ban, Jones, Hannah M., Comandini, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200067/ https://www.ncbi.nlm.nih.gov/pubmed/35233913 http://dx.doi.org/10.1111/cts.13253 |
Ejemplares similares
-
A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder
por: Fagiolini, Andrea, et al.
Publicado: (2020) -
Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study
por: Shrashimirova, Milena, et al.
Publicado: (2023) -
Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone–Atomoxetine Interaction
por: Oggianu, Laura, et al.
Publicado: (2020) -
PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023) -
Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects
por: Tellone, Valeria, et al.
Publicado: (2020)